Browse PRKAB2

Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF16561 Glycogen recognition site of AMP-activated protein kinase
PF04739 5'-AMP-activated protein kinase beta subunit
Function

Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3).

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006820 anion transport
GO:0006839 mitochondrial transport
GO:0006853 carnitine shuttle
GO:0006869 lipid transport
GO:0006914 autophagy
GO:0007050 cell cycle arrest
GO:0010565 regulation of cellular ketone metabolic process
GO:0010876 lipid localization
GO:0015711 organic anion transport
GO:0015718 monocarboxylic acid transport
GO:0015908 fatty acid transport
GO:0015909 long-chain fatty acid transport
GO:0016053 organic acid biosynthetic process
GO:0016236 macroautophagy
GO:0019216 regulation of lipid metabolic process
GO:0019217 regulation of fatty acid metabolic process
GO:0032365 intracellular lipid transport
GO:0042180 cellular ketone metabolic process
GO:0042304 regulation of fatty acid biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0045786 negative regulation of cell cycle
GO:0046394 carboxylic acid biosynthetic process
GO:0046890 regulation of lipid biosynthetic process
GO:0046942 carboxylic acid transport
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072331 signal transduction by p53 class mediator
GO:0098656 anion transmembrane transport
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1990542 mitochondrial transmembrane transport
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004679 AMP-activated protein kinase activity
Cellular Component GO:0031588 nucleotide-activated protein kinase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04068 FoxO signaling pathway
hsa04152 AMPK signaling pathway
hsa04530 Tight junction
hsa04710 Circadian rhythm
hsa04910 Insulin signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa04921 Oxytocin signaling pathway
hsa04922 Glucagon signaling pathway
Reactome R-HSA-163680: AMPK inhibits chREBP transcriptional activation activity
R-HSA-2151209: Activation of PPARGC1A (PGC-1alpha) by phosphorylation
R-HSA-2262752: Cellular responses to stress
R-HSA-380972: Energy dependent regulation of mTOR by LKB1-AMPK
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-200425: Import of palmitoyl-CoA into the mitochondrial matrix
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-163685: Integration of energy metabolism
R-HSA-1632852: Macroautophagy
R-HSA-199991: Membrane Trafficking
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1592230: Mitochondrial biogenesis
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-109704: PI3K Cascade
R-HSA-109703: PKB-mediated events
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-162582: Signal Transduction
R-HSA-74752: Signaling by Insulin receptor
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-1445148: Translocation of GLUT4 to the plasma membrane
R-HSA-5653656: Vesicle-mediated transport
R-HSA-165159: mTOR signalling
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRKAB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRKAB2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRKAB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1050.746
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0770.958
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1340.888
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2450.523
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0490.97
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6150.711
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0020.996
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1320.936
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1160.951
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1730.872
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9680.481
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0460.539
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRKAB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRKAB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRKAB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRKAB2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRKAB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRKAB2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRKAB2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRKAB2
Nameprotein kinase, AMP-activated, beta 2 non-catalytic subunit
Aliases AMPK beta 2; 5'-AMP-activated protein kinase, beta-2 subunit; AMP-activated protein kinase beta 2 non-cataly ......
Chromosomal Location1q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRKAB2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRKAB2.
ID Name Drug Type Targets #Targets
DB00131Adenosine monophosphateSmall MoleculeACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, ......15
DB00945Acetylsalicylic acidSmall MoleculeAKR1C1, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, ......18